EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Altered O‐glycosylation of β 1 ‐adrenergic receptor N‐terminal single‐nucleotide variants modulates receptor processing and functional activity

Hanna E Tuhkanen, Ilona J Haasiomäki, Jarkko J Lackman, Christoffer K Goth, S Orvokki Mattila, Zilu Ye, Sergey Y Vakhrushev, Johanna Magga iD, Risto Kerkelä, Henrik Clausen, Katrine T Schjoldager, Ulla E Petäjä-Repo iD

The FEBS Journal · 2025

DOI: 10.1111/febs.17257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Hanna E Tuhkanen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Center Oulu and Research Unit of Biomedicine and Internal Medicine, University of Oulu, Finland. Hauptthemen laut MEDLINE: Polymorphism, Single Nucleotide, Receptors, Adrenergic, beta-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Fonden, Sydäntutkimussäätiö, Paavo Nurmen Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N‐terminal nonsynonymous single‐nucleotide polymorphisms (SNPs) of G protein‐coupled receptors (GPCRs) are common and often affect receptor post‐translational modifications. Their functional implications are, however, largely unknown. We have previously shown that the human β 1 ‐adrenergic receptor (β 1 AR) is O‐glycosylated in the N‐terminal extracellular domain by polypeptide GalNAc transferase‐2 that co‐regulates receptor proteolytic cleavage. Here, we demonstrate that the common S49G and the rare A29T and R31Q SNPs alter these modifications, leading to distinct effects on receptor processing. This was achieved by in vitro O‐glycosylation assays, analysis of native receptor N‐terminal O‐glycopeptides, and expression of receptor variants in cell lines and neonatal rat ventricular cardiomyocytes deficient in O‐glycosylation. The SNPs eliminated (S49G) or introduced (A29T) regulatory O‐glycosites that enhanced or inhibited cleavage at the adjacent sites (P 52 ↓L 53 and R 31 ↓L 32 ), respectively, or abolished the major site at R 31 ↓L 32 (R31Q). The inhibition of proteolysis of the T29 and Q31 variants correlated with increased full‐length receptor levels at the cell surface. Furthermore, the S49 variant showed increased isoproterenol‐mediated signaling in an enhanced bystander bioluminescence energy transfer β‐arrestin2 recruitment assay in a coordinated manner with the common C‐terminal R389G polymorphism. As Gly at position 49 is ancestral in placental mammals, the results suggest that its exchange to Ser has created a β 1 AR gain‐of‐function phenotype in humans. This study provides evidence for regulatory mechanisms by which GPCR SNPs outside canonical domains that govern ligand binding and activation can alter receptor processing and function. Further studies on other GPCR SNPs with clinical importance as drug targets are thus warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymorphism, Single NucleotideReceptors, Adrenergic, beta-1GlycosylationHumansAnimalsRatsMyocytes, CardiacProtein Processing, Post-TranslationalHEK293 CellsIsoproterenolProteolysis

Stichwörter der Autor:innen

G protein‐coupled receptorO‐glycosylationproteolytic processingsingle‐nucleotide polymorphismβ1‐adrenergic receptor

Substanzen

Receptors, Adrenergic, beta-1IsoproterenolADRB1 protein, human

Autor:innen und Institutionen

  • Medical Research Center Oulu and Research Unit of Biomedicine and Internal Medicine, University of Oulu, Finland.
  • Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

ORCID-Profile: Johanna Magga, Ulla E Petäjä-Repo

Förderung

  • Novo Nordisk Fonden
  • Sydäntutkimussäätiö
  • Paavo Nurmen Säätiö
  • Magnus Ehrnrooth Foundation
  • Suomen Kulttuurirahasto
  • Danish Research Council
  • Terveyden Tutkimuksen Toimikunta
  • Aarne Koskelon Säätiö

Zitieren

APA

Tuhkanen, H. E., Haasiomäki, I. J., Lackman, J. J., Goth, C. K., Mattila, S. O., Ye, Z., Vakhrushev, S. Y., Magga, J., Kerkelä, R., Clausen, H., Schjoldager, K. T., & Petäjä-Repo, U. E. (2025). Altered O‐glycosylation of β 1 ‐adrenergic receptor N‐terminal single‐nucleotide variants modulates receptor processing and functional activity. The FEBS Journal. https://doi.org/10.1111/febs.17257

Vancouver

Tuhkanen HE, Haasiomäki IJ, Lackman JJ, Goth CK, Mattila SO, Ye Z, et al. Altered O‐glycosylation of β 1 ‐adrenergic receptor N‐terminal single‐nucleotide variants modulates receptor processing and functional activity. The FEBS Journal. 2025. doi:10.1111/febs.17257

BibTeX
@article{Tuhkanen2025,
  author = {Tuhkanen, Hanna E and Haasiomäki, Ilona J and Lackman, Jarkko J and Goth, Christoffer K and Mattila, S Orvokki and Ye, Zilu and Vakhrushev, Sergey Y and Magga, Johanna and Kerkelä, Risto and Clausen, Henrik and Schjoldager, Katrine T and Petäjä-Repo, Ulla E},
  title = {Altered O‐glycosylation of β 1 ‐adrenergic receptor N‐terminal single‐nucleotide variants modulates receptor processing and functional activity},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.17257}
}
Kostenlos starten →